Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU, Indian And US Leaders Share Global Outlook To 2030

Association Heads Set Out Views Following Launch Of IGBA ‘Vision’ Whitepaper

Executive Summary

At an IGBA panel discussion moderated by Generics Bulletin’s editor, three industry leaders representing Europe, India and the US debated the key issues facing the international off-patent sector today.

You may also be interested in...



IGBA Sets Out Industry Vision To 2030

A whitepaper setting out a comprehensive vision for the off-patent industry to 2030 has been launched by the IGBA. Highlighting the industry’s current contribution to healthcare, it also sets out a path ahead for the generics and biosimilars sector, pointing out headwinds as well as opportunities.

Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing

Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.

GGB Awards Offer One More Week To Enter

Off-patent industry players from around the globe now have an extra week to submit their achievements to the Global Generics & Biosimilars Awards 2021 being held on 10 November, after the entry deadline was extended by a week to 6 August. Pharmacloud has also joined the event, sponsoring the Leader of the Year category.

Topics

UsernamePublicRestriction

Register

GB151112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;